Correction Pharmaceutical Group Co., Ltd. is a large-scale modern pharmaceutical enterprise with well-known products in the market, such as Starshu, Correction Brand Xiaomi, Weidaning Spray, and Yiqi and Blood Nourishing Oral Liquid, and is involved in the big health industry/tourism/pension industry
Founded in May 1995 by Chairman Xiu Laigui, Amendment Group is a large-scale modern private pharmaceutical enterprise integrating scientific research, production and marketing of patent medicines, chemical pharmaceuticals and biopharmaceuticals, drug chain management and standard cultivation of Chinese herbal medicines. While highlighting the main business of pharmaceuticals, it has entered the health industry, tourism and real estate industry, and implemented diversified development. While basing itself on the whole country, we will face the world and develop the international market.
By the end of 2016, the group had 127 subsidiaries, more than 100,000 employees, and stock assets of 17 billion yuan. It has 24 dosage forms, more than 2,000 varieties of medicines and health care products, including 109 exclusive varieties. More than 50 varieties of more than 100 million varieties have been sold, more than 20 varieties of more than 1 billion have been sold, and more than 50 varieties with development potential, among which more than a dozen large varieties of more than 500 million yuan have been cultivated through secondary development, such as Lung Ning, Xiao Mi Suppository, Liuwei Rehmannia Rehmannia, Neck and Waist Health, and Qi and Blood Nourishment; The use of new preparation technology to develop Starshu pellets and dispersible tablets has ensured the correction of the leading brand of gastric medicine in China. It has a domestic first-class scientific research system integrating scientific and technological management, innovative drug research and transformation of new technological achievements, has more than 300 middle and senior technical experts, has obtained more than 700 authorized patents, and won 7 national scientific and technological progress awards. The group invests about 1 billion yuan in scientific research every year. Recombinant urate oxidase for injection, a new national first-class biological drug that will be put into production and marketed, is used for the treatment of tumor lysis syndrome, and is the second company in the world to produce this product after Sanofi. PEGylated urate oxidase and PEGylated follicle-stimulating hormone are the first in China and will fill the gap in China.
Launched the international cooperation and development platform for a series of genetically recombinant hypoglycemic drugs, jointly developed a series of hypoglycemic genetic engineering drugs such as insulin aspart and insulin detemir with India, and implemented the industrialization technology development of large-scale medicinal and edible fungi. Correction has a large OTC market network in the country.
Amendment Pharmaceutical Group is committed to charity and social welfare undertakings, and actively participates in public welfare activities such as earthquake and flood relief, donation to education, etc., and is worth more than 1 billion yuan for various charitable donations and glorious causes.
To build a century-old correction and create a national brand, the pharmaceutical industry should strive to achieve the goal of 100 billion yuan in sales revenue within 10 years, reach the goal of one trillion yuan by 2030, and become one of the world's top 100 pharmaceutical companies.
